Skip to main content

Table 1 Overview of RCT characteristics

From: Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review

Characteristic Category RCT published between
Jan.2004 –Mar. 2014 (n. 9),
N. (%)
RCTs published between
Apr.2014 – Jun.2018 (n. 8),
N. (%)
Total (n. 17),
N. (%)
International (if more than one country) No 8 (88.9) 8 (100) 16 (94.1)
Yes 1 (11.1) 0 (0) 1 (5.9)
Industry supported (fully or in part) No 6 (66.7) 7 (87.5) 13 (76.5)
Yes 3 (33.3) 1 (12.5) 4 (23.5)
PRO endpoint Primary 5 (55.6) 0 (0) 5 (29.4)
Secondary 4 (44.4) 8 (100) 12 (70.6)
Secondary paper on PRO No 8 (88.9) 8 (100) 16 (94.1)
Yes 1 (11.1) 0 (0) 1 (5.9)
Length of PRO assessment during RCT Up to 6 months 4 (44.5) 6 (75) 10 (58.8)
Up to 1 year 2 (22.2) 1 (12.5) 3 (17.7)
More than 1 year 3 (33.3) 1 (12.5) 4 (23.5)
Overall study sample size <=200 7 (77.8) 7 (87.5) 14 (82.3)
> 200 2 (22.2) 1 (12.5) 3 (17.7)